Foxo4 Dri Research
Product image coming soon
FOXO4-DRI: Senescent Cell Biology and Apoptotic Signalling Research
FOXO4-DRI is a synthetic D-retro-inverso (DRI) peptide studied in laboratory settings for its role in senescent cell biology. It is designed to interfere with the FOXO4-p53 protein-protein interaction that is studied as a survival mechanism in senescent cells, making it a research tool for investigating cellular senescence and apoptotic signalling.
Molecular Data
| Property | Value |
|---|---|
| Molecular weight | Approximately 2.8 kDa |
| Peptide type | D-retro-inverso (DRI) peptide |
| Target interaction | FOXO4-p53 protein-protein interaction |
| Based on | FOXO4 helix-2 domain sequence |
| Purity | greater than or equal to 98% as verified by HPLC |
| Form | Lyophilised powder |
| Storage | -20 degrees C, protected from light and moisture |
| Reconstitution | DMSO or sterile water recommended |
FOXO4-DRI: Senescent Cell Apoptotic Signalling
D-Retro-Inverso Peptide Design
FOXO4-DRI is a D-retro-inverso peptide — a peptide composed entirely of D-amino acids (the mirror-image form of natural L-amino acids) arranged in the reverse sequence of the native FOXO4 helix-2 domain. This design strategy creates a peptide that:
Resists proteolytic degradation. D-amino acids are not recognised by most cellular proteases, which evolved to cleave L-amino acid peptide bonds. This extends the research tool's stability in cell culture and in vivo models dramatically compared to the native L-peptide sequence.
Maintains structural mimicry. The combination of D-amino acids and reversed sequence creates a mirror image of the native helix conformation, preserving the spatial arrangement of key side chains required for protein-protein interaction inhibition.
Cell-permeability. FOXO4-DRI contains a cell-penetrating segment derived from the FOXO4 sequence that enables intracellular delivery — important for accessing the nucleus where FOXO4-p53 interactions occur.
Cellular Senescence Research Context
Cellular senescence is a state of stable cell cycle arrest studied extensively in the context of ageing, cancer, and tissue dysfunction. Senescent cells accumulate with age and in damaged tissues, and they secrete a complex mixture of cytokines, matrix metalloproteases, and growth factors known as the senescence-associated secretory phenotype (SASP).
Research has identified that senescent cells upregulate survival pathways that prevent their removal by apoptosis. The FOXO4-p53 interaction has been studied as one such survival mechanism: in senescent cells, FOXO4 is proposed to sequester p53 in the nucleus, preventing p53-mediated apoptosis transcription.
FOXO4-p53 Interaction Research
FOXO4-DRI is used as a tool compound for studying the functional consequences of FOXO4-p53 interaction disruption in cell models. Research has examined changes in nuclear p53 localisation, caspase activation, and apoptotic signalling in senescent cells following FOXO4-DRI treatment.
This connects FOXO4-DRI research to broader cellular ageing biology studied with NAD+ (sirtuin-mediated senescence pathways) and MOTS-c (mitochondrial stress signalling relevant to cellular ageing).
Senolytic Research Tool Comparison
| Compound | Target | Mechanism | Cell type selectivity |
|---|---|---|---|
| FOXO4-DRI | FOXO4-p53 interaction | D-retro-inverso peptide | Senescent cells |
| Navitoclax (ABT-263) | BCL-2/BCL-XL | BH3 mimetic | Broad — platelet toxicity |
| Dasatinib + Quercetin | Src kinase / flavonoid targets | Multi-target | Broad |
| HSP90 inhibitors | HSP90 client proteins | Chaperone disruption | Partial selectivity |
The Senescence-Associated Secretory Phenotype (SASP)
Senescent cells do not simply stop dividing — they remain metabolically active and secrete a complex mixture of inflammatory mediators known as the SASP. Key SASP components studied in laboratory models include:
- Pro-inflammatory cytokines: IL-6, IL-8, IL-1alpha, IL-1beta, TNF-alpha
- Matrix metalloproteinases: MMP-1, MMP-3, MMP-9, MMP-10, MMP-13
- Growth factors: VEGF, HGF, EGF
- Chemokines: CXCL1, CXCL2, CXCL5
The SASP is regulated in part through NFkB and mTOR signalling. Research using FOXO4-DRI to induce senescent cell apoptosis examines whether SASP factors decline following senescent cell clearance — a key endpoint in senolytic research.
Frequently Asked Questions
What makes the D-retro-inverso design of FOXO4-DRI particularly useful?
Standard L-peptides are rapidly degraded by cellular proteases. By using all D-amino acids in the reverse sequence (retro-inverso design), FOXO4-DRI achieves complete resistance to proteolytic degradation while maintaining the spatial arrangement of key side chains needed for FOXO4-p53 interaction inhibition. This protease resistance means the peptide can be used in cell culture for extended periods without degradation, and can penetrate cells and reach the nucleus — where FOXO4-p53 interactions occur — intact.
How do researchers identify senescent cells for FOXO4-DRI research?
Common senescence markers used to confirm cell populations in FOXO4-DRI research include: SA-beta-galactosidase (beta-galactosidase activity at pH 6.0, a classic senescence marker), p21 and p16 expression (cyclin-dependent kinase inhibitors upregulated in senescence), H2AX gamma foci (DNA damage markers), SAHF (senescence-associated heterochromatin foci), and SASP cytokine secretion. Researchers typically use multiple markers together since no single marker is fully specific for senescence.
Published Research References
For laboratory and analytical research purposes only. Not for human or veterinary use. No dosage or administration guidance is provided or implied.
Related research compounds: NAD+ | MOTS-c | 5-Amino-1MQ
Cellular Senescence: The SASP in Detail
The senescence-associated secretory phenotype (SASP) that FOXO4-DRI research targets is not a fixed programme but a dynamic, evolving secretome that changes with time in senescence and in response to microenvironmental signals. Key SASP components studied in laboratory models include:
Pro-inflammatory cytokines: IL-6 and IL-8 are the most consistently elevated SASP factors across cell types. Both are regulated by NFkB and C/EBPbeta transcription factors, which are constitutively active in senescent cells. IL-6 drives paracrine senescence (inducing senescence in neighbouring cells) and promotes an inflammatory microenvironment. IL-8 is a neutrophil and macrophage chemoattractant.
Matrix metalloproteinases: MMP-1, MMP-3, MMP-9, MMP-10, and MMP-13 are secreted by senescent cells and degrade extracellular matrix components. MMP secretion is proposed to contribute to tissue dysfunction associated with senescent cell accumulation in aged tissues and tumour microenvironments.
Growth factors: VEGF, HGF, and EGF secreted by senescent cells can paradoxically promote proliferation in nearby pre-malignant cells — the non-cell-autonomous tumour-promoting effect of SASP that complicates the original view of senescence as purely tumour-suppressive.
IGFBP-3: Inhibits IGF-1 signalling in the microenvironment, contributing to tissue atrophy and impaired regeneration in aged tissues with high senescent cell burden.
FOXO4's Unique Senescent Cell Role
What makes FOXO4 mechanistically interesting in senescence research is that it appears to play a selective survival role specifically in senescent cells rather than proliferating cells. In actively proliferating cells, FOXO4 is exported from the nucleus and functionally inactive. In senescent cells, FOXO4 localises to the nucleus and physically interacts with p53, sequestering p53 in a nuclear complex that prevents p53-mediated transcription of pro-apoptotic genes (PUMA, NOXA, BAX).
FOXO4-DRI disrupts this nuclear FOXO4-p53 complex by competing with FOXO4 for p53 binding. Freed p53 can then translocate to mitochondria and activate the intrinsic apoptosis pathway in senescent cells — which have chronically elevated p53 activity due to persistent DNA damage signalling — while proliferating cells (with lower p53 activity) are relatively unaffected. This provides the mechanistic basis for the apparent selectivity of FOXO4-DRI for senescent over non-senescent cells.
Frequently Asked Questions
How is senescence confirmed in research models using FOXO4-DRI?
Senescence is typically confirmed using multiple complementary markers: SA-beta-galactosidase activity (enzymatic activity at pH 6.0, visualised with X-gal staining), p21 and p16 protein expression by Western blot, SAHF (senescence-associated heterochromatin foci) by H3K9me3 immunofluorescence, and gamma-H2AX foci indicating persistent DNA damage. SASP cytokine measurement (IL-6, IL-8 by ELISA) in conditioned media confirms the secretory phenotype. No single marker is definitive; multiple positive markers together provide high confidence in senescence status.
What is the difference between senolysis and senomorphism as research approaches?
Senolysis (killing senescent cells, as studied with FOXO4-DRI) and senomorphism (suppressing the SASP without killing senescent cells) are complementary research approaches to understanding senescence biology. Senolytics like FOXO4-DRI provide a clean mechanistic tool: if removing senescent cells reduces tissue dysfunction, this implicates the senescent cells themselves. Senomorphic approaches (suppressing NFkB or mTOR in senescent cells to reduce SASP) separate the question of cell survival from secretory function. Using both approaches in parallel research designs provides more complete mechanistic insight.
Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide